Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 7/20 | 0.50 |
| ▸ | GRIN2A | Q12879 | 6/20 | 0.50 |
| ▸ | GRIN1 | Q05586 | 6/20 | 0.50 |
| ▸ | GRIN2D | O15399 | 5/20 | 0.50 |
| ▸ | GRIN3B | O60391 | 5/20 | 0.50 |
| ▸ | ADRA1D | P25100 | 5/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.50 |
| ▸ | ADRA1B | P35368 | 5/20 | 0.50 |
| ▸ | GRIN2C | Q14957 | 5/20 | 0.50 |
| ▸ | GRIN3A | Q8TCU5 | 5/20 | 0.50 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.41 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6875117 | 0.82 | SIGMAR1 (0.49) | GRIN2BGRIN2AGRIN1 | |
| SCHEMBL7699990 | 0.81 | GRIN2B (0.47) | GRIN2BGRIN2AGRIN1GRIN2DGRIN3B | |
| SCHEMBL6873990 | 0.81 | GRIN2B (0.47) | GRIN2BGRIN2AGRIN1GRIN2DGRIN3B | |
| SCHEMBL7705024 | 0.81 | GRIN2B (0.47) | GRIN2BGRIN2AGRIN1GRIN2DGRIN3B | |
| SCHEMBL6873993 | 0.81 | GRIN2B (0.47) | GRIN2BGRIN2AGRIN1GRIN2DGRIN3B | |
| SCHEMBL7896159 | 0.81 | GRIN2B (0.47) | GRIN2BGRIN2AGRIN1GRIN2DGRIN3B | |
| SCHEMBL7700004 | 0.81 | GRIN2B (0.47) | GRIN2BGRIN2AGRIN1GRIN2DGRIN3B | |
| SCHEMBL6874312 | 0.81 | SIGMAR1 (0.50) | GRIN2BGRIN1 | |
| Hydrochloric Acid SCHEMBL6873860 | 0.81 | SIGMAR1 (0.48) | GRIN2BGRIN2A | |
| SCHEMBL6880262 | 0.81 | SIGMAR1 (0.50) | GRIN2BGRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1278728-B1 | PYRROLIDINE AND PIPERIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | HOFFMANN LA ROCHE (CH) | 2004-08-25 | — | — | EP | claimed |
| EP-1278728-A1 | PYRROLIDINE AND PIPERIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-01-29 | — | — | EP | claimed |
| US-6451819-B2 | PYRROLIDINE-3-YL-SULFANYL, OR SUFONYL OR SUFINYL DERIVATIVES USED IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | HOFFMANN-LA ROCHE INC. | 2002-09-17 | — | — | US | claimed |
| US-20010047031-A1 | Heterocyclic compounds useful as NMDA receptor selective subtype blockers | HOFFMANN-LA ROCHE INC. | 2001-11-29 | — | — | US | claimed |
| WO-2001081303-A1 | PYRROLIDINE AND PIPERIDINE DERIVATIVES AND THEIR USE FOR THE TREAMENT OF NEURODEGENERATIVE DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-11-01 | — | — | WO | claimed |
| EP-1278728-B1 | PYRROLIDINE AND PIPERIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | HOFFMANN LA ROCHE (CH) | 2004-08-25 | — | — | EP | disclosed |
| EP-1278728-A1 | PYRROLIDINE AND PIPERIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-01-29 | — | — | EP | disclosed |
| US-6451819-B2 | PYRROLIDINE-3-YL-SULFANYL, OR SUFONYL OR SUFINYL DERIVATIVES USED IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | HOFFMANN-LA ROCHE INC. | 2002-09-17 | — | — | US | disclosed |
| US-20010047031-A1 | Heterocyclic compounds useful as NMDA receptor selective subtype blockers | HOFFMANN-LA ROCHE INC. | 2001-11-29 | — | — | US | disclosed |
| WO-2001081303-A1 | PYRROLIDINE AND PIPERIDINE DERIVATIVES AND THEIR USE FOR THE TREAMENT OF NEURODEGENERATIVE DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010047031-A1 | Heterocyclic compounds useful as NMDA receptor selective subtype blockers | GRIN1, GRM1, GRIN2B | GRIN2B 3/4885GRIN2A 6/4885GRIN1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.